成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

GW3965 HCl

GW3965 HCl是一種有效的，選擇性LXR激動劑，作用于hLXRα和hLXRβ，無細胞試驗中EC50分別為190和30 nM。

GW3965 HCl Chemical Structure

GW3965 HCl Chemical Structure

CAS: 405911-17-3

規(guī)格 價格 庫存 購買數量
10mM (1mL in DMSO) 1966.57 現貨
5mg 790.51 現貨
50mg 4654.57 現貨
200mg 7944.3 現貨
1g 27764.1 現貨
更大包裝 有超大折扣

400-668-6834

info@selleck.cn
免費分裝
免費預溶

常與GW3965 HCl一起在實驗中被使用的化合物

Carboplatin

在MAS98.12模型中，GW3965和Carboplatin比單獨Carboplatin顯著減小相對腫瘤體積。

Haugen MH, et al. Mol Oncol. 2023 Jun 21.

Pioglitazone

GW3965和Pioglitazone組合預處理原代小膠質細胞可導致iNOS轉錄物顯著減少。

Skerrett R, et al. J Biol Chem. 2015 Aug 28;290(35):21591-602.

Bexarotene

GW3965HCl和Bexarotene誘導急性髓系白血病(AML)細胞的分化和凋亡。

Serhan N, et al. Cancers (Basel). 2020 Jun 29;12(7):1725.

Gefitinib

GW3965可以增加Gefitinib誘導的HCC827/GR-8-2細胞系細胞凋亡和細胞周期停滯。

Hu Y, et al. Oncotarget. 2017 Feb 28;8(9):15802-15814.

Navitoclax (ABT-263)

在A375異種移植模型中，GW3965和Navitoclax(ABT-263)聯(lián)合治療比單獨使用任一藥物更能明顯抑制腫瘤生長。

Nguyen TTT, et al. EMBO Mol Med. 2019 Oct;11(10):e10769.

GW3965 HCl相關產品

細胞實驗數據示例

細胞系 實驗類型 給藥濃度 孵育時間 活性描述 文獻信息
HEK293 10 uM 20 hrs Activation of rat LXRbeta expressed in HEK293 cells co-expressing human RXRalpha at 10 uM after 20 hrs by luciferase reporter gene assay 28006909
HEK293 10 uM 20 hrs Activation of human LXRalpha expressed in HEK293 cells co-expressing human RXRalpha at 10 uM after 20 hrs by luciferase reporter gene assay 28006909
HepG2 Function assay 500 nM Inhibition of 2-(3-(3-((2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino)propoxy)phenyl)acetic acid-induced srebp1c mRNA expression in human HepG2 cells at 500 nM 18800767
HepG2 Function assay 500 nM Inhibition of 2-(3-(3-((2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino)propoxy)phenyl)acetic acid-induced fas mRNA expression in human HepG2 cells at 500 nM 18800767
RAW264.7 Function assay 1 uM Reduction of LPS-stimulated iNOS gene expression in mouse RAW264.7 cells expressing LXRalpha at 1 uM by luciferase reporter gene assay 18800767
RAW264.7 Function assay 1 uM Inhibition of LPS-stimulated nuclear co-repressor release from iNOS promoter in mouse RAW264.7 cells at 1 uM by RT-PCR 18800767
HeLa Function assay 1 uM Induction of LXRbeta SUMOylation by SUMO2 in human HeLa cells at 1 uM by Western blot analysis 18800767
HeLa Function assay 1 uM Induction of LXRbeta SUMOylation by SUMO3 in human HeLa cells at 1 uM by Western blot analysis 18800767
HeLa Function assay 1 uM Induction of LXRalpha SUMOylation by SUMO3 in human HeLa cells at 1 uM by Western blot analysis 18800767
THP1 Antiinflammatory assay 6 hrs Antiinflammatory activity against human THP1 cells assessed as inhibition of LPS-stimulated IL6 production after 6 hrs by ELISA, IC50 = 0.02 μM. 18800767
COS7 Function assay 16 hrs Agonist activity at human LXRbeta receptor transfected in COS7 cells after 16 hrs by reporter transactivation assay, EC50 = 0.015 μM. 17587573
THP1 Function assay 18 hrs Induction of cholesterol efflux in THP1 cells after 18 hrs, EC50 = 0.01 μM. 17416521
RAW264.7 Function assay 24 hrs Induction of [3H]cholesterol efflux in mouse RAW264.7 cells loaded with acetylated-LDL after 24 hrs, EC50 = 0.029 μM. 19717304
SH-SY5Y Function assay 24 hrs Agonist activity at human LXRbeta expressed in human SH-SY5Y cells co-transfected with Gal4-LBD after 24 hrs by luciferase reporter gene assay, EC50 = 0.13 μM. 19264481
SH-SY5Y Function assay 24 hrs Agonist activity at human LXRalpha expressed in human SH-SY5Y cells co-transfected with Gal4-LBD after 24 hrs by luciferase reporter gene assay, EC50 = 0.31 μM. 19264481
CHOK1 Function assay 24 hrs Agonist activity at Gal4-tagged LXRbeta (unknown origin) expressed in CHOK1 cells after 24 hrs by luciferase reporter gene assay, EC50 = 0.42 μM. 25677664
CHOK1 Function assay 24 hrs Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells after 24 hrs by luciferase reporter gene assay, EC50 = 1.3 μM. 25677664
THP1 Function assay Agonist activity at GAL-linked human LXRbeta expressed in THP1 cells assessed as stimulation of co-activator recruitment by FRET assay, EC50 = 0.027 μM. 17665897
COS7 Function assay Activation of LXRbeta co-transfected in COS7 cells with RXRalpha by reporter transactivation assay, EC50 = 0.015 μM. 17416521
THP1 Function assay Induction of cholesterol efflux in THP1 cells, EC50 = 0.01 μM. 17587573
THP1 Function assay Stimulation of [3H]cholesterol efflux in human THP1 foam cells loaded with ac-LDL, EC50 = 0.031 μM. 18973288
CV1 Function assay Antagonist activity at LXRbeta ligand binding domain assessed as inhibition of T1317-induced transcriptional activity in african green monkey CV1 cells co-transfected with Gal4-SRC1 by luciferase reporter assay, IC50 = 0.03981 μM. 20345102
THP1 Function assay Agonist activity at GAL-linked human LXRalpha expressed in THP1 cells assessed as stimulation of coactivator recruitment by FRET assay, EC50 = 0.097 μM. 17665897
CV1 Function assay Antagonist activity at LXRalpha ligand binding domain assessed as inhibition of T1317-induced transcriptional activity in african green monkey CV1 cells co-transfected with Gal4-SRC1 by luciferase reporter assay, IC50 = 0.1 μM. 20345102
HepG2 Function assay Effect on SREBP1c gene expression in human HepG2 cells, EC50 = 0.21 μM. 18973288
HuH7 Function assay Agonist activity at human recombinant LXRbeta ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay, EC50 = 0.31 μM. 18973288
CHO Function assay Agonist activity at human LXR beta receptor expressed in CHO cells by reporter assay, EC50 = 0.41 μM. 17034119
THP1 Function assay Effect on ABCA1 gene expression in human differentiated THP1 cells, EC50 = 0.434 μM. 18973288
CV1 Function assay Agonist activity at LXRbeta ligand binding domain-mediated transcriptional activity in african green monkey CV1 cells co-transfected with Gal4-SRC1 by luciferase reporter assay, EC50 = 0.50119 μM. 20345102
HuH7 Function assay Agonist activity at human recombinant LXRalpha ligand binding domain in human HuH7 cells co-transfected with fused Gal4-DBD by transactivation assay, EC50 = 0.66 μM. 18973288
CV1 Function assay Agonist activity at LXRalpha ligand binding domain-mediated transcriptional activity in african green monkey CV1 cells co-transfected with Gal4-SRC1 by luciferase reporter assay, EC50 = 0.79433 μM. 20345102
HepG2 Function assay Effect on triglyceride accumulation in human HepG2 cells, EC50 = 2.002 μM. 18973288
DAOY qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells 29435139
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells 29435139
BT-37 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells 29435139
NB-EBc1 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells 29435139
BT-12 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells 29435139
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells 29435139
RD qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells 29435139
MG 63 (6-TG R) qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells 29435139
Rh30 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells 29435139
Rh41 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells 29435139
點擊查看更多細胞系數據

生物活性

產品描述 GW3965 HCl是一種有效的，選擇性LXR激動劑，作用于hLXRα和hLXRβ，無細胞試驗中EC50分別為190和30 nM。
靶點
hLXRβ [1]
(Cell-free assay)		 LXRα/SRC1?LiSA [1]
(Cell-free assay)		 hLXRα [1]
(Cell-free assay)
30 nM(EC50) 125 nM(EC50) 190 nM(EC50)

化學信息&溶解度

分子量 618.51 分子式

C33H31ClF3NO3.HCl
CAS號 405911-17-3 SDF Download GW3965 HCl SDF
Smiles C1=CC=C(C=C1)C(CN(CCCOC2=CC=CC(=C2)CC(=O)O)CC3=C(C(=CC=C3)C(F)(F)F)Cl)C4=CC=CC=C4.Cl
儲存條件(自收到貨起)

體外溶解度
批次：

DMSO : 100 mg/mL ( (161.67 mM) ；DMSO吸濕會降低化合物溶解度，請使用新開封DMSO)

Water : Insoluble

Ethanol : Insoluble

摩爾濃度計算器

體內溶解度
批次：

現配現用，請按從左到右的順序依次添加，澄清后再加入下一溶劑

 動物體內配方計算器

實驗計算

摩爾濃度計算器

質量 濃度 體積 分子量

動物體內配方計算器（澄清溶液）

第一步：請輸入基本實驗信息（考慮到實驗過程中的損耗，建議多配一只動物的藥量）

mg/kg g μL 只

第二步：請輸入動物體內配方組成（配方適用于不溶于水的藥物；不同批次藥物配方比例不同，請聯(lián)系Selleck為您提供正確的澄清溶液配方）

% DMSO % % Tween 80 % ddH2O
%DMSO %

計算結果：

工作液濃度： mg/ml；

DMSO母液配制方法： mg 藥物溶于μL DMSO溶液（母液濃度mg/mL，注：如該濃度超過該批次藥物DMSO溶解度，請先聯(lián)系Selleck）；

體內配方配制方法：取μL DMSO母液，加入μL PEG300，混勻澄清后加入μL Tween 80，混勻澄清后加入μL ddH2O，混勻澄清。

體內配方配制方法：取μL DMSO母液，加入μL Corn oil，混勻澄清。

注意：1. 首先保證母液是澄清的；
2.一定要按照順序依次將溶劑加入，進行下一步操作之前必須保證上一步操作得到的是澄清的溶液，可采用渦旋、超聲或水浴加熱等物理方法助溶。

技術支持

在訂購、運輸、儲存和使用我們的產品的任何階段，您遇到的任何問題，均可以通過撥打我們的熱線電話400-668-6834，或者技術支持郵箱tech@selleck.cn，直接聯(lián)系到我們。我們會在24小時內盡快聯(lián)系您。

操作手冊

如果有其他問題，請給我們留言。

* 必填項

請輸入您的姓名
請輸入您的郵箱地址 請輸入一個有效的郵箱地址
請寫點東西給我們

常見問題及建議解決方法

問題 1:
How to formulate the compound for mouse in vivo experiment?

回答：
S2630 GW3965 HCl can be dissolved in 2% DMSO/30% PEG 300/dd H2O at 10 mg/mL as a homogeneous suspension. This vehicle is suitable for oral gavage to mice.

Tags: buy GW3965 HCl | GW3965 HCl supplier | purchase GW3965 HCl | GW3965 HCl cost | GW3965 HCl manufacturer | order GW3965 HCl | GW3965 HCl distributor
在線咨詢
聯(lián)系我們